Key result
Antithrombin III combined with low-dose heparin limits VTE to ~7% after total hip replacement.
Why the study?
Does antithrombin III combined with low-dose heparin prevent venous thromboembolic disease in patients undergoing total hip or knee replacement?
RCT
Randomized
Does antithrombin III combined with low-dose heparin prevent venous thromboembolic disease in patients undergoing total hip or knee replacement?
Antithrombin III replacement combined with low-dose heparin is an effective prophylactic regimen for preventing venous thromboembolic disease following total hip replacement.
Answers are grounded in this paper and cite their sources.
Supports antithrombin III plus low-dose heparin for VTE prophylaxis after hip replacement; confirms benefit in postoperative orthopedic patients.
The use of antithrombin III (ATIII) replacement in combination with low-dose heparin therapy in prevention of postoperative venous thrombosis in patients following total hip replacement or total knee replacement was evaluated. A randomized prospective venographically controlled trial in hip replacement compared treatment with dextran 40 with a regimen of ATIII (1,500 units preoperatively and 1,000 units daily for five days) and low-dose heparin. Patients receiving ATIII/heparin had significantly higher postoperative ATIII concentrations than dextran-treated patients and also had a low incidence of venous thromboembolic disease (7 percent). The ATIII/heparin regimen was well tolerated with no increase in bleeding or significant prolongation of the activated partial thromboplastin time. Two cohorts of patients undergoing total knee replacement were studied using different doses of ATIII in combination with heparin. An initial 10 patients were treated with the same ATIII dose used for patients undergoing total hip replacement, with a 50 percent incidence of venous thrombosis. A second group of 11 patients was treated with twice the dose of ATIII, and an incidence of venous thrombosis of 27 percent was found. The higher ATIII dose resulted in significantly higher ATIII concentrations and maintained the postoperative ATIII concentration above normal. Among patients receiving prophylaxis with either warfarin. dextran, or ATIII/heparin, no clear association was found between reduced ATIII concentrations and occurrence of venous thrombosis. It is concluded that ATIII replacement following total hip or knee replacement corrects the postoperative ATIII deficiency and that the combination of ATIII and low-dose heparin is an effective prophylactic regimen following total hip replacement.
No takes yet. Share an insight, caveat, or question.
Francis et al. (1989) conducted an RCT in Venous thromboembolic disease after total hip or total knee replacement. Antithrombin III (ATIII) and low-dose heparin vs. Dextran 40 was evaluated on Incidence of venous thromboembolic disease. Antithrombin III combined with low-dose heparin was an effective prophylactic regimen following total hip replacement, resulting in a 7% incidence of venous thromboembolic disease.
Synapse has enriched 10 related papers. Consider them for comparative context: